Key points are not available for this paper at this time.
Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
Share your take
Add a clinician perspective alongside expert commentary.
Shepherd et al. (2005) studied this question.